

# The Inhibitory Effects of *Protaetia brevitarsis seulensis* Larvae Extract on Human Platelet Aggregation and Glycoprotein IIb/IIIa Expression

Hyuk-Woo Kwon<sup>1,2</sup>, Man Hee Rhee<sup>3,4</sup>, and Jung-Hae Shin<sup>3,4</sup>

<sup>1</sup>Department of Biomedical Laboratory Science and <sup>2</sup>Microbiological Resource Research Institute, Far East University, Chungbuk 27601, Korea

<sup>3</sup>Department of Veterinary Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Korea

<sup>4</sup>Cardiovascular Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Korea

**ABSTRACT:** The white-spotted flower chafer, *Protaetia brevitarsis seulensis*, is used as a traditional remedy against liver cirrhosis, hepatitis, and hepatic cancer. In this study, we investigated if *P. brevitarsis* extract (PBE) inhibited platelet aggregation via integrin  $\alpha$ IIb/ $\beta$ <sub>3</sub> regulation. We observed that PBE inhibited  $\alpha$ IIb/ $\beta$ <sub>3</sub> activation by regulating the cyclic nucleotides, cyclic adenosine monophosphate and cyclic guanosine monophosphate. Additionally, PBE affected phosphatidylinositol-3 kinase, Akt, SYK, glycogen synthase kinase-3 $\alpha$ / $\beta$ , cytosolic phospholipase A<sub>2</sub>, and p38 expression, which are signal transduction molecules expressed by platelets, and consequently suppressed  $\alpha$ IIb/ $\beta$ <sub>3</sub> activity and thromboxane A<sub>2</sub> generation. Taken together, PBE showed strong antiplatelet effects and may be used to block thrombosis- and platelet-mediated cardiovascular diseases.

**Keywords:** cyclic nucleotides, glycoprotein IIb/IIIa, platelet aggregation, thrombosis

## INTRODUCTION

Platelets form blood clots to maintain cellular hemostasis. Therefore, correct platelet regulation is required to suppress harmful events during cardiovascular disease, thus antithrombosis therapies are required to specifically target platelet inhibition pathways (Jackson, 2011). However, contrary to expectations, many antiplatelet agents do not ameliorate cardiovascular disease mortality rates (Lee et al., 2021), which often occur due to sudden symptom onset. Therefore, researchers must focus on prevention rather than cure, and identify natural materials which prevent these diseases. Generally, natural materials elicit few side effects, and those products with antiplatelet effects can prevent thrombosis and cardiovascular disease via regular administration (Irfan et al., 2020; Sharifi-Rad et al., 2020). Therefore, in an attempt to identify new antithrombosis drugs, we focused on the antiplatelet activity of *Protaetia brevitarsis seulensis* extract (PBE) from larvae. *P. brevitarsis* larvae are used in ethnomedicine to combat liver cirrhosis, hepatitis, and hepatic cancer (Yoo et al., 2022). In Korea, *P. brevitarsis* is registered as a food ma-

terial by the Ministry of Food and Drug Safety, therefore, we evaluated PBE effects on platelet activity.

Damaged blood vessels contain exposed collagen fibers which bind to integrins on platelets (Moroi and Jung, 2004), initiates platelet activation, and elevates calcium (Ca<sup>2+</sup>) concentrations in the cytosol. The first mechanism involved in calcium regulation is Ca<sup>2+</sup> mobilization. Platelet activation thus releases calcium from the endoplasmic reticulum into the cytosol (Varga-Szabo et al., 2009). Next, a deficiency of stored Ca<sup>2+</sup> in the endoplasmic reticulum can facilitate extracellular Ca<sup>2+</sup> influx. Elevated intracellular Ca<sup>2+</sup> concentrations ([Ca<sup>2+</sup>]<sub>i</sub>) activate Ca<sup>2+</sup>-dependent kinases which trigger granule release (Farndale, 2006). This agonist-induced signaling cascade or “inside-out signaling” activates glycoprotein IIb/IIIa (integrin  $\alpha$ IIb/ $\beta$ <sub>3</sub>), which then binds to other platelets via adhesive proteins (fibrinogen and fibronectin), and  $\alpha$ IIb/ $\beta$ <sub>3</sub>-mediated signaling triggers platelet aggregation (Phillips et al., 2001). Therefore, in this study, we examined the inhibitory effects of PBE on platelet aggregation.

Received 3 April 2023; Revised 23 May 2023; Accepted 26 June 2023; Published online 30 September 2023

Correspondence to Jung-Hae Shin, E-mail: mlsjshin@naver.com

© 2023 The Korean Society of Food Science and Nutrition.

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## MATERIALS AND METHODS

### Materials

*P. brevitarsis* larvae were obtained from Chungbuk Agricultural Research and Extension Services. Dried larvae were pulverized in a grinder and powdered material successively extracted in 70% ethanol (350 mL) using a Soxhlet apparatus at 150°C for 1 h. The PBE was concentrated in a vacuum evaporator, lyophilized, redissolved in dimethyl sulfoxide, and adjusted to 100 mg/mL. Human platelets were obtained from the Korean Red Cross Blood Center. Phospho-IP<sub>3</sub>R, Phospho-vasodilator-stimulated phosphoprotein (VASP) (Ser<sup>157</sup> and Ser<sup>239</sup>), Phospho-PI<sub>3</sub>K, Phospho-Akt (Ser<sup>473</sup> and Thr<sup>308</sup>), Phospho-GSK-3 $\alpha/\beta$ ,  $\beta$ -actin, phosphor-SYK, phosphor-p38, phosphor-ERK (1/2), and phosphor-cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) antibodies were purchased from Cell Signaling Technology. Alexa Fluor 488-conjugated fibrinogen and fura 2-acetoxymethyl (Fura-2 AM) antibodies were purchased from Invitrogen. Platelet agonists, collagen, and thrombin were bought from Chrono-Log Corp.. Cyclic nucleotides [cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)] assay kits and thapsigargin were purchased from Cayman Chemical.

### Platelet aggregation analysis

Platelets were separated and washed in washing buffer (pH 6.5) and adjusted in suspension buffer (pH 6.9) to 10<sup>8</sup>/mL. PBE was poorly soluble in water, therefore it was dissolved in dimethyl sulfoxide (0.1%). Platelets (10<sup>8</sup>/mL) were preincubated with different PBE concentrations (75, 100, 150, and 200  $\mu$ M) at 37°C while stirring, and collagen was added for full platelet aggregation using an aggregometer (Chrono-Log Corp.).

### Cytotoxicity analysis

We investigated if PBE concentrations affected lactate dehydrogenase (LDH) levels in platelets. Platelets (10<sup>8</sup>/mL) were preincubated with different PBE concentrations for 15 min at 37°C while stirring. After centrifugation at 12,000 g, supernatants were separated and LDH levels analyzed using an enzyme-linked immunosorbent assay (ELISA) kit and ELISA plate reader (TECAN).

### cAMP and cGMP analysis

Platelets (10<sup>8</sup>/mL) were preincubated with different PBE concentrations (75, 100, 150, and 200  $\mu$ M) for 5 min at 37°C. After platelet aggregation was stopped by ethanol (80%), platelets were centrifuged at 500 g, and separated supernatants used to determine cyclic nucleotide (cAMP and cGMP) levels using cAMP- and cGMP-ELISA kits and an ELISA plate reader.

### Ca<sup>2+</sup> mobilization and influx analysis

To measure [Ca<sup>2+</sup>]<sub>i</sub>, the Grynkiewicz method (Grynkiewicz et al., 1985) was used. Platelets were incubated with Fura-2 AM for 20 min, washed, and platelet concentrations adjusted to 10<sup>8</sup>/mL using suspension buffer. Platelets (10<sup>8</sup>/mL) were incubated with different PBE concentrations (75, 100, 150, and 200  $\mu$ M) at 37°C for 5 min and then stimulated with collagen (2.5  $\mu$ g/mL). To detect Ca<sup>2+</sup> influx, platelets were stimulated with 1  $\mu$ M thapsigargin in the presence of 100  $\mu$ M EGTA, and 2 mM calcium was added at 3 min. Ca<sup>2+</sup> concentrations were analyzed using a fluorescence spectrophotometer (F-2700, Hitachi).

### Western blotting

To investigate phosphorylation events, platelet aggregation was performed and platelet lysates quantified. Proteins were separated by electrophoresis and then transferred to polyvinylidene fluoride membranes. Primary antibodies were incubated with membranes overnight at 4°C, and after washing (Tris-buffered saline plus 0.1% Tween 20), a secondary antibody was added and incubated with membranes at room temperature for 2 h. Then, protein signals were developed in a darkroom. Western blotting results were calculated using the Quantity One program (Bio-Rad Laboratories).

### Analyzing $\alpha$ IIB/ $\beta$ <sub>3</sub> binding to fibrinogen

To examine fibrinogen binding, fibrinogen dye (Alexa Fluor 488) was used in platelet aggregation experiments. During platelet aggregation, artificial fibrinogen binds to activated platelet integrin  $\alpha$ IIB/ $\beta$ <sub>3</sub> and induces strong aggregation. Platelet binding to fibrinogen dye increases fluorescence and if  $\alpha$ IIB/ $\beta$ <sub>3</sub> activity is inhibited by PBE, fluorescence is reduced. We tested platelet aggregation using different PBE concentrations (75, 100, 150, and 200  $\mu$ M) for 5 min. Then, platelet and fibrinogen dye binding was fixed in paraformaldehyde, transferred to flow cytometry tubes, and binding forces analyzed using a BD Biosciences flow cytometer.

### Analyzing $\alpha$ IIB/ $\beta$ <sub>3</sub> adhesion to fibronectin

Fibronectin is a plasma protein and functions as an adhesive protein to bind platelet integrin  $\alpha$ IIB/ $\beta$ <sub>3</sub>. Therefore, we analyzed  $\alpha$ IIB/ $\beta$ <sub>3</sub> activity in fibronectin-coated wells. Platelets and different PBE concentrations (75, 100, 150, and 200  $\mu$ M) were added to fibronectin-coated wells and stimulated by collagen. In normal reactions, platelets adhere to fibronectin-coated wells to form thin films. After reactions, wells were washed twice in buffer, and platelet layers stained using cell staining solution. After this, extract solution was added to extract stained platelet layers and absorbances analyzed using an ELISA plate reader to determine platelet adhesion.

### Analyzing thromboxane A<sub>2</sub> (TXA<sub>2</sub>)

Activated platelets synthesize TXA<sub>2</sub> via an “inside-out signaling cascade.” TXA<sub>2</sub> acts as a strong agonist and is quickly converted to thromboxane B<sub>2</sub> (TXB<sub>2</sub>), which was measured. After collagen-induced platelet aggregation with PBE, indomethacin was added to stop reactions and mixtures centrifuged briefly to generate TXB<sub>2</sub>-containing supernatants, which were analyzed using an ELISA plate reader.

### Data analysis

Results were expressed as the mean±standard deviation; the number of observations varied between different groups. To determine significant differences between groups, we used one way analysis of variance, and the Tukey–Kramer method was used for *posthoc* comparisons in IBM SPSS Statistics 21 software (IBM Corp.). A *P*<0.05 value was considered statistically significant.

## RESULTS

### Platelet aggregation and cytotoxicity

We used collagen (2.5 μg/mL) to promote full platelet aggregation; platelets (10<sup>8</sup>/mL) were stirred for 2 min with different PBE concentrations, reacted for 5 min, and then collagen added. As shown Fig. 1A, platelets stimulated with collagen were strongly aggregated, but were dose-dependently inhibited by PBE; the half maximal inhibitory concentration was 119.5 μg/mL (Fig. 1B). To confirm PBE cytotoxic effects toward platelets, LDH release

after platelet incubation with PBE was analyzed. As shown Fig. 1C, PBE did not affect cytotoxicity.


### Variations in cAMP and cGMP levels

The most well-known inhibitory molecules secreted from platelets are cyclic nucleotides (cAMP and cGMP), which are synthesized from nitric oxide and prostacyclin in endothelial cells (Haslam et al., 1978). In platelets, inositol 1,4,5-triphosphate receptor (IP<sub>3</sub>R), Rap1b, glycoprotein Ibβ, phosphodiesterase 3, and VASP are major cAMP and cGMP substrates. These signaling molecules can affect [Ca<sup>2+</sup>]<sub>i</sub> mobilization and αIIb/β<sub>3</sub> activity (Schwarz et al., 2001). As shown Fig. 2, PBE increased cAMP and cGMP concentrations.


### IP<sub>3</sub>R-, ERK-, and p38-phosphorylation

We examined calcium concentrations and the phosphorylation of Ca<sup>2+</sup>-related signaling molecules. We first focused on Ca<sup>2+</sup> mobilization. As shown Fig. 3A, collagen addition increased Ca<sup>2+</sup> mobilization but was dose-dependently suppressed by PBE. Ca<sup>2+</sup> regulation also occurs via Ca<sup>2+</sup> influx, therefore, we investigated if PBE affected this. As shown Fig. 3B, thapsigargin-elevated Ca<sup>2+</sup> influx was dose-dependently decreased by PBE.


Next, we investigated if PBE could control IP<sub>3</sub>R phosphorylation and ERK dephosphorylation. IP<sub>3</sub>R is located on the surface of the endoplasmic reticulum and cAMP and cGMP are negative regulators of Ca<sup>2+</sup> mobilization. IP<sub>3</sub>R phosphorylation by cAMP/cGMP-dependent kinases can block Ca<sup>2+</sup> mobilization. In addition, the depletion of stored Ca<sup>2+</sup> can initiate Ca<sup>2+</sup> influx, and ERK is an impor-



**Fig. 1.** *Protactia brevitarsis seulensis* extract (PBE) effects on platelet aggregation. (A) PBE effects on collagen-induced human platelet aggregation. (B) Half maximal inhibitory concentration (IC<sub>50</sub>) value of PBE on collagen-induced human platelet aggregation. (C) PBE effects on cytotoxicity. Data are presented as the mean±SD (n=4). \**P*<0.05, \*\**P*<0.01 vs. collagen-stimulated human platelets. NS, not significant.



**Fig. 2.** *Protoetia brevitarsis seulensis* extract (PBE) effects on cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) production. (A) PBE effects on collagen-induced cAMP production. (B) PBE effects on collagen-induced cGMP production. Data are presented as the mean±SD (n=4). \**P*<0.05 vs. collagen-stimulated human platelets.




**Fig. 3.** *Protoetia brevitarsis seulensis* extract (PBE) effects on [Ca<sup>2+</sup>]<sub>i</sub> mobilization and IP<sub>3</sub>R/ERK/p38 phosphorylation. (A) PBE effects on collagen-induced [Ca<sup>2+</sup>]<sub>i</sub> mobilization. (B) PBE effects on thapsigargin-induced Ca<sup>2+</sup> influx. (C) PBE effects on collagen-induced IP<sub>3</sub>R and ERK phosphorylation. Data are presented as the mean±SD (n=4). \**P*<0.05, \*\**P*<0.01 vs. agonist (collagen or thapsigargin-stimulated human platelets).

tant factor controlling this (Rosado and Sage, 2001). We observed that PBE increased IP<sub>3</sub>R phosphorylation and decreased ERK phosphorylation when induced by collagen (Fig. 3C).

#### TXA<sub>2</sub>, cPLA<sub>2</sub>, and p38-phosphorylation

TXA<sub>2</sub> acts as an agonist which stimulates platelet activation (Needleman et al., 1976). As shown Fig. 4A, TXA<sub>2</sub> was dose-dependently inhibited by PBE. It is accepted



**Fig. 4.** *Protoetia brevitarsis seulensis* extract (PBE) effects on thromboxane A<sub>2</sub> generation and cPLA<sub>2</sub>/p38 phosphorylation. (A) PBE effects on collagen-induced thromboxane A<sub>2</sub> generation. (B) PBE effects on collagen-induced cPLA<sub>2</sub>/p38 phosphorylation. Data are presented as the mean±SD (n=4). \**P*<0.05, \*\**P*<0.01 vs. collagen-stimulated human platelets.

that two signaling molecules affect TXA<sub>2</sub> synthesis; cPLA<sub>2</sub> and mitogen-activated protein kinase p38 (p38) are TXA<sub>2</sub> regulators (Kramer et al., 1996). As shown Fig. 4B, collagen-elevated cPLA<sub>2</sub> and p38 phosphorylation was inhibited by PBE.

### Fibrinogen binding and fibronectin adhesion

Next, we examined  $\alpha$ IIb/ $\beta$ <sub>3</sub> function, which can affect platelet aggregation and adhesion. As shown Fig. 5A and 5B, PBE suppressed collagen-elevated binding forces. To confirm PBE effects on  $\alpha$ IIb/ $\beta$ <sub>3</sub> activity, we analyzed its activity using fibronectin. As shown Fig. 5C, PBE strongly suppressed platelet adhesion and reduced  $\alpha$ IIb/ $\beta$ <sub>3</sub> activity. Thus, PBE inhibited  $\alpha$ IIb/ $\beta$ <sub>3</sub> structural changes.

### PI<sub>3</sub>K-, Akt-, GSK-3-, SYK-phosphorylation, and VASP-dephosphorylation

We next analyzed the phosphorylation of  $\alpha$ IIb/ $\beta$ <sub>3</sub>-related signaling molecules (PI<sub>3</sub>K/Akt/GSK-3/SYK/VASP), which are essential regulators of the  $\alpha$ IIb/ $\beta$ <sub>3</sub>-mediated signaling cascade (Sudo et al., 2003; Guidetti et al., 2015). We confirmed that PBE significantly reduced PI<sub>3</sub>K/Akt/GSK-3/SYK-phosphorylation and elevated VASP (Ser<sup>157</sup>, Ser<sup>239</sup>) phosphorylation (Fig. 5).


## DISCUSSION

In normal circulation, vascular endothelial cells release

prostaglandin I<sub>2</sub> and nitric oxide to promote cAMP and cGMP nucleotide production, which are the most important second messengers involved in the negative feedback of platelet actions (Smolenski, 2012) and are regulated by adenylate, guanylate cyclase, and phosphodiesterases (Haslam et al., 1999; Gresele et al., 2011). The cAMP/cGMP-dependent protein kinase phosphorylates various substrates such as actin binding protein, heat shock protein 27, G-protein  $\alpha_{13}$  subunit, glycoprotein Ib $\beta$  subunit, inositol 1,4,5-trisphosphate receptor, Rap1b, caldesmon, VASP, and phosphodiesterase 3 (Schwarz et al., 2001). Therefore, we investigated if PBE affected cAMP and cGMP production and showed that it increased these levels (Fig. 5B).

Next, we examined if PBE regulated [Ca<sup>2+</sup>]<sub>i</sub> mobilization and Ca<sup>2+</sup> influx levels via phosphorylation and dephosphorylation mechanisms, as shown Fig. 3A, PBE inhibited [Ca<sup>2+</sup>]<sub>i</sub> mobilization. Another Ca<sup>2+</sup> regulation pathway occurs via influx, therefore, we evaluated thapsigargin-induced Ca<sup>2+</sup> influx effects by PBE. As shown Fig. 3B, thapsigargin-induced Ca<sup>2+</sup> influx was suppressed by PBE. Additionally, we confirmed that PBE regulated Ca<sup>2+</sup> signaling by regulating IP<sub>3</sub>R phosphorylation and ERK dephosphorylation (Fig. 3C).

TXA<sub>2</sub> is a platelet activator, therefore we examined if PBE could regulate TXA<sub>2</sub> concentrations and associated signaling molecules (cPLA<sub>2</sub> and p38). p38 activates cPLA<sub>2</sub> via phosphorylation (Kramer et al., 1996). Activated cPLA<sub>2</sub> hydrolyzes polyunsaturated fatty acids in mem-



**Fig. 5.** *Protactia brevitarsis seulensis* extract (PBE) effects on fibrinogen binding to  $\alpha$ IIb/ $\beta$ <sub>3</sub> and fibronectin adhesion. (A) Flow cytometry histograms show fibrinogen binding. (B) PBE effects on collagen-induced fibrinogen binding (%). (C) PBE effects on collagen-induced fibronectin adhesion. Data are presented as the mean  $\pm$  SD (n=4). \* $P$ <0.05, \*\* $P$ <0.01 vs. collagen-stimulated human platelets.

brane phospholipids, with arachidonic acid release. Next, cyclooxygenase-1 and TXA<sub>2</sub> synthase generate TXA<sub>2</sub>, which is released from the platelet cytoplasm and activates other platelets (FitzGerald, 1991). We confirmed that PBE suppressed TXA<sub>2</sub> levels via the dephosphorylation of signaling molecules (Fig. 4).

The  $\alpha$ IIb/ $\beta$ <sub>3</sub>-mediated signaling cascade is important in hemostasis. Therefore, we investigated  $\alpha$ IIb/ $\beta$ <sub>3</sub> activity and related signaling molecules. As shown Fig. 5, PBE suppressed fibrinogen binding and fibronectin adhesion. We next evaluated if PBE could inhibit  $\alpha$ IIb/ $\beta$ <sub>3</sub>-related signaling molecules. PI<sub>3</sub>K/Akt/GSK-3 is a signaling molecule that facilitates  $\alpha$ IIb/ $\beta$ <sub>3</sub> activation (Chen et al., 2004; Moroi and Watson, 2015; Valet et al., 2016; Moore et al., 2021). SYK is a 72 kDa tyrosine kinase that is stimulated and phosphorylated by platelet agonists adenosine diphosphate, thrombin, and collagen, and also functions after  $\alpha$ IIb/ $\beta$ <sub>3</sub> activation and promotes platelet aggregation (Clark et al., 1994; Keely and Parise, 1996). VASP helps regulate actin filament dynamics and platelet shape, but its phosphorylation can inhibit platelets. We investigated PBE effects on PI<sub>3</sub>K/Akt/GSK-3 phosphorylation and showed (Fig. 6) that PBE inhibited collagen-elevated PI<sub>3</sub>K, Akt (Ser<sup>473</sup> and Thr<sup>308</sup>), and GSK-3 $\alpha$ / $\beta$  phosphorylation. Additionally, PBE decreased collagen-induced SYK and elevated VASP (Ser<sup>157</sup>, Ser<sup>239</sup>) phosphorylation. Therefore, PBE inhibited  $\alpha$ IIb/ $\beta$ <sub>3</sub> activation via  $\alpha$ IIb/ $\beta$ <sub>3</sub>-related signaling molecules.

To characterize PBE effects on platelet aggregation, component analysis research was conducted and alkaloid com-

ponents identified (Lee et al., 2017). Among alkaloids, 5-hydroxyindolin-2-one (5-HI) and (1R,3S)-1-methyl-1,2,3,4-tetrahydro-b-carboline-3-carboxylic acid showed antiplatelet and anticoagulation activity and also bleeding time elongation (Lee et al., 2017; Choi et al., 2019). In our previous study, we used 5-HI to evaluate antiplatelet mechanisms in platelets and identified several inhibitory signaling molecules (Kwon et al., 2022). Therefore, antiplatelet PBE effects may be due to indole alkaloid effects, thus these putative PBE components should be characterized and confirmed.


Finally, we showed that PBE decreased platelet aggregation, intracellular Ca concentrations, and  $\alpha$ IIb/ $\beta$ <sub>3</sub> activation via cyclic nucleotides and phosphoprotein regulation. Therefore, *P. brevitarsis* is useful in antithrombosis applications.

## FUNDING

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF 2020R111A1A01067709).

## AUTHOR DISCLOSURE STATEMENT

The authors declare no conflict of interest.



**Fig. 6.** *Protoetia brevitarsis seoulensis* extract (PBE) effects on PI<sub>3</sub>K/Akt/GSK-3 $\alpha$ / $\beta$ , SYK, and VASP phosphorylation. Data are presented as the mean $\pm$ SD (n=4). \* $P < 0.05$  vs. collagen-stimulated human platelets.

## AUTHOR CONTRIBUTIONS

Concept and design: JHS. Analysis and interpretation: HWK. Data collection: HWK. Writing the article: MHR, JHS. Critical revision of the article: HWK. Final approval of the article: all authors. Statistical analysis: HWK. Obtained funding: JHS. Overall responsibility: JHS.

## REFERENCES

- Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. *Blood*. 2004. 104:1703-1710.
- Choi IH, Yu R, Lim YJ, Choi GS, Choi SU, Hwang JI, et al. Anti-thrombotic efficacy of *Protoetia brevitarsis* extract. *J Environ Sci Int*. 2019. 28:639-643.
- Clark EA, Shattil SJ, Brugge JS. Regulation of protein tyrosine kinases in platelets. *Trends Biochem Sci*. 1994. 19:464-469.
- Farndale RW. Collagen-induced platelet activation. *Blood Cells Mol Dis*. 2006. 36:162-165.
- FitzGerald GA. Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. *Am J Cardiol*. 1991. 68:11B-15B.
- Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. *Br J Clin Pharmacol*. 2011. 72:634-646.
- Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties. *J Biol Chem*. 1985. 260:3440-3450.
- Guidetti GF, Canobbio I, Torti M. PI3K/Akt in platelet integrin signaling and implications in thrombosis. *Adv Biol Regul*. 2015. 59:36-52.
- Haslam RJ, Davidson MM, Fox JE, Lynham JA. Cyclic nucleotides in platelet function. *Thromb Haemost*. 1978. 40:232-240.
- Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. *Thromb Haemost*. 1999. 82:412-423.
- Irfan M, Kim M, Rhee MH. Anti-platelet role of Korean ginseng and ginsenosides in cardiovascular diseases. *J Ginseng Res*. 2020. 44:24-32.
- Jackson SP. Arterial thrombosis—insidious, unpredictable and deadly. *Nat Med*. 2011. 17:1423-1436.
- Keely PJ, Parise LV. The  $\alpha 2\beta 1$  integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase C $\gamma 2$  in platelets. *J Biol Chem*. 1996. 271:26668-26676.
- Kramer RM, Roberts EF, Um SL, Börsch-Haubold AG, Watson SP, Fisher MJ, et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. *J Biol Chem*. 1996. 271:27723-27729.
- Kwon HW, Kim SD, Rhee MH, Shin JH. Pharmacological actions of 5-hydroxyindolin-2 on modulation of platelet functions and thrombus formation via thromboxane A2 inhibition and cAMP production. *Int J Mol Sci*. 2022. 23:14545. <https://doi.org/10.3390/ijms232314545>
- Lee HH, Cho SMJ, Lee H, Baek J, Bae JH, Chung WJ, et al. Korea Heart Disease Fact Sheet 2020: analysis of nationwide data. *Korean Circ J*. 2021. 51:495-503.
- Lee J, Lee W, Kim MA, Hwang JS, Na M, Bae JS. Inhibition of platelet aggregation and thrombosis by indole alkaloids isolated from the edible insect *Protoetia brevitarsis seulensis* (Kolbe). *J Cell Mol Med*. 2017. 21:1217-1227.
- Moore SF, Agbani EO, Wersäll A, Poole AW, Williams CM, Zhao X, et al. Opposing roles of GSK3 $\alpha$  and GSK3 $\beta$  phosphorylation in platelet function and thrombosis. *Int J Mol Sci*. 2021. 22:10656. <https://doi.org/10.3390/ijms221910656>
- Moroi AJ, Watson SP. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3 $\alpha/\beta$ . *J Thromb Haemost*. 2015. 13:1139-1150.
- Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. *Thromb Res*. 2004. 114:221-233.
- Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. *Nature*. 1976. 261:558-560.
- Phillips DR, Nannizzi-Alaimo L, Prasad KS.  $\beta 3$  tyrosine phosphorylation in  $\alpha IIb\beta 3$  (platelet membrane GP IIb-IIIa) outside-in integrin signaling. *Thromb Haemost*. 2001. 86:246-258.
- Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. *Biochem Pharmacol*. 2001. 62:1153-1161.
- Sharifi-Rad J, Rodrigues CF, Sharopov F, Docea AO, Can Karaca A, Sharifi-Rad M, et al. Diet, lifestyle and cardiovascular diseases: Linking pathophysiology to cardioprotective effects of natural bioactive compounds. *Int J Environ Res Public Health*. 2020. 17:2326. <https://doi.org/10.3390/ijerph17072326>
- Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. *J Thromb Haemost*. 2012. 10:167-176.
- Sudo T, Ito H, Kimura Y. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. *Platelets*. 2003. 14:381-390.
- Valet C, Severin S, Chicanne G, Laurent PA, Gaits-Iacovoni F, Gratacap MP, et al. The role of class I, II and III PI 3-kinases in platelet production and activation and their implication in thrombosis. *Adv Biol Regul*. 2016. 61:33-41.
- Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost*. 2009. 7:1057-1066.
- Yoo BG, Hong JP, Song HY, Byun EH. Immuno-modulatory activity of hot water extracts isolated from *Protoetia brevitarsis seulensis* larvae through MAPKs and NF- $\kappa$ B pathways in macrophages. *J Korean Soc Food Sci Nutr*. 2022. 51:100-106.